Valneva Shares Sink 40% YTD as Travel Vaccine Woes Drive Aggressive Cost-Cutting and an Uncertain AGM

Valneva’s annual shareholder meeting on 25 June in Lyon is shaping up to be a tense affair. The vaccine specialist enters the gathering with its stock trading at €2.30, just 8% above a 52-week trough of €2.13, and a year-to-date decline of roughly 40%. Management will face pointed questions as the company navigates a restructuring that is already trimming headcount and slashing costs.

The numbers tell a stark story. In the first quarter of 2026, Valneva posted total revenue of €30.9 million, a sharp drop from €49.2 million a year earlier. Net losses ballooned to €32.1 million from €9.2 million in the prior-year period. The culprit, according to the company, is a slump in demand for travel vaccines as geopolitical uncertainty curbs global movement. That weakness has forced Valneva to lower its full-year product revenue guidance to a range of €135 million to €150 million, down from the earlier forecast of €145 million to €160 million.

To stem the bleeding, Valneva launched a restructuring programme in April that will cut 10–15% of its global workforce. Operational expenses are targeted to fall by 25% to 35% compared with 2025 levels. The cost reduction plans were originally detailed when the company released its AGM documents on Monday, and management has since embarked on an investor roadshow that includes appearances at the Jefferies conference and forums hosted by Oddo BHF and BNP Paribas in Paris.

Should investors sell immediately? Or is it worth buying Valneva?

Analyst sentiment remains divided. First Berlin Research reaffirmed a Buy rating in late May, but Goldman Sachs downgraded the stock to Sell in April, citing a challenging outlook and material uncertainties after disappointing results from the Lyme disease vaccine candidate. Meanwhile, Wall Street Zen slapped a Sell rating on the shares this week. The 200-day moving average of €3.73 sits more than 38% above the current price, underscoring how far the stock has fallen. The relative strength index at 37.2 suggests the shares are technically oversold, yet no sustained bounce has materialised.

The one bright spot continues to be the Lyme disease vaccine LB6V, developed in partnership with Pfizer. Phase 3 data showed efficacy exceeding 70%, and the partners plan to file for approval in the second half of 2026. If regulators give the green light, the shot could reach the market in 2027. Until then, Valneva must convince shareholders that its aggressive cost-cutting will stabilise the business and keep the pipeline on track—a task that grows more difficult with each passing quarter of falling revenue and widening losses.

Ad

Valneva Stock: New Analysis - 9 June

Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Valneva analysis...

en | FR0004056851 | VALNEVA | boerse | 69508507 |